A NOVEL HORMONE THAT PROMOTES BONE RESORPTION AND USES THEREOF
The disclosure describes the use of anti-IGFBP1 antibodies to inhibit the bone loss-inducing properties of FGF21. This can be applied in the context of FGF21 treatment for obesity and/or diabetes, or in menopause-induced bone loss, such as osteoporosis.
1 . A method of treating menopause-induced bone loss in a subject comprising administering to a subject in need thereof an anti-IGFBP1 antibody.
2 . The method of claim 1 , wherein said antibody is part of a polyclonal antibody preparation.
3 . The method of claim 1 , wherein said antibody is a monoclonal antibody.
4 . The method of claim 3 , wherein said antibody is a humanized antibody, a chimeric antibody, an antibody fragment, a bispecific antibody or a single chain antibody.
5 . The method of claim 1 , wherein said antibody is administered systemically.
6 . The method of claim 1 , wherein said antibody is administered local or regional to a site of bone loss or potential bone loss.
7 . The method of claim 1 , wherein said subject is a human subject.
8 . The method of claim 1 , wherein said subject is a non-human animal subject.
9 . The method of claim 1 , menopause is age-related.
10 . The method of claim 1 , menopause is surgery-related.
11 . A method of treating a subject for bone resorption induced by FGF21 therapy comprising administering to a subject in need thereof an anti-IGFBP1 antibody.
12 . The method of claim 11 , wherein said antibody is part of a polyclonal antibody preparation.
13 . The method of claim 11 , wherein said antibody is a monoclonal antibody.
14 . The method of claim 13 , wherein said antibody is a humanized antibody, a chimeric antibody, an antibody fragment, a bispecific antibody or a single chain antibody.
15 . The method of claim 11 , wherein said antibody is administered systemically.
16 . The method of claim 11 , wherein said antibody is administered local or regional to a site of bone resorption or potential bone resorption.
17 . The method of claim 11 , wherein said subject is a human subject.
18 . The method of claim 11 , wherein said subject is a non-human animal subject.
19 . The method of claim 11 , wherein said antibody is co-administered with FGF21.
20 . The method of claim 11 , wherein said antibody is administered before or after FGF21.
21 . A method of treating FGF21-induced bone loss/resorption comprising administering to a subject in need thereof an integrin β-1 inhibitor.
22 . The method of claim 21 , wherein said FGF21-induced bone loss/resorption is menopause-related.
23 . The method of claim 21 , wherein said FGF21-induced bone loss/resorption is FGF21 therapy-related.
24 . The method of claim 13 , wherein said inhibitor is an anti-integrin β-1 antibody, an integrin β-1 siRNA, an integrin β-1 fragment or sharpin.
25 . The method of claim 21 , wherein said inhibitor is administered systemically.
26 . The method of claim 21 , wherein said inhibitor is administered local or regional to a site of bone loss/resorption or potential bone loss/resorption.
27 . The method of claim 21 , wherein said subject is a human subject.
28 . The method of claim 21 , wherein said subject is a non-human animal subject.
29 . The method of claim 23 , wherein said inhibitor is co-administered with FGF21.
30 . The method of claim 23 , wherein said inhibitor is administered before or after FGF21.